The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

Abstract Introduction The advances in immune checkpoint inhibitors (ICIs) were relatively slow in rare tumors. Therefore, we conducted a multi‐center study evaluating the efficacy of ICI monotherapy and the combination of ICIs with chemotherapy (CT) in patients with advanced rare tumors. Methods In...

Full description

Bibliographic Details
Main Authors: Deniz Can Guven, Musa Baris Aykan, Harun Muglu, Ertugrul Bayram, Kaan Helvaci, Bengü Dursun, Melisa Celayir, Elvin Chelebiyev, Erdinc Nayir, Mustafa Erman, Ahmet Sezer, Yuksel Urun, Umut Demirci, Ozlem Er, Umut Disel, Ahmet Bilici, Cagatay Arslan, Nuri Karadurmus, Saadettin Kilickap
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Cancer Medicine
Subjects:
immune checkpoint inhibitor
immunotherapy
rare tumor
sarcoma
Online Access:https://doi.org/10.1002/cam4.6869

Internet

https://doi.org/10.1002/cam4.6869

Similar Items